Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer...
Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA
SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )
4 Oct 2019
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )
4 Oct 2019
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
4 Oct 2019
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1...
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )
4 Oct 2019
IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer
Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain
IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )
4 Oct 2019
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )
4 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019
Blood first assay screening in patients with ALK positive NSCLC
Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA
Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )
4 Oct 2019
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative ad...
Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )
4 Oct 2019
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO gui...
Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )
4 Oct 2019
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line...
Dr Thomas Yau - The University of Hong Kong, Hong Kong
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )
4 Oct 2019